Next Article in Journal
Predictive and Preventive Mucosal Communications in Particulate Matter Exposure-Linked Renal Distress
Previous Article in Journal
Integrating Patient-Specific Information into Logic Models of Complex Diseases: Application to Acute Myeloid Leukemia
Previous Article in Special Issue
A Predictive Model and Risk Factors for Case Fatality of COVID-19
Open AccessFeature PaperArticle

Statin Therapy and the Risk of COVID-19: A Cohort Study of the National Health Insurance Service in South Korea

by 1,†, 1,† and 1,2,*
1
Department of Anesthesiology and Pain Medicine, Seoul National University Bundang Hospital, Gumi-ro 173 Beon-gil, Bundang-gu, Seongnam-si, Gyeonggi-do 13620, Korea
2
Department of Anesthesiology and Pain Medicine, Seoul National University College of Medicine, 103 Daehak-ro, Jongno-gu, Seoul 03080, Korea
*
Author to whom correspondence should be addressed.
These authors made an equal contribution as co-first authors.
Academic Editor: Philip P. Foster
J. Pers. Med. 2021, 11(2), 116; https://doi.org/10.3390/jpm11020116
Received: 27 January 2021 / Revised: 5 February 2021 / Accepted: 6 February 2021 / Published: 10 February 2021
(This article belongs to the Special Issue COVID-19 Related Complications)
We aimed to investigate whether statin therapy is associated with the incidence of coronavirus disease 2019 (COVID-19) among the South Korean population. In addition, we examined whether statin therapy affects hospital mortality among COVID-19 patients. The National Health Insurance Service (NHIS)-COVID-19 database in South Korea was used for data extraction for this population-based cohort study. A total of 122,040 adult individuals, with 22,633 (18.5%) in the statin therapy group and 101,697 (91.5%) in the control group, were included in the analysis. Among them, 7780 (6.4%) individuals were diagnosed with COVID-19 and hospital mortality occurred in 251 (3.2%) COVID-19 cases. After propensity score matching, logistic regression analysis showed that the odds of developing COVID-19 were 35% lower in the statin therapy group than in the control group (odds ratio: 0.65, 95% confidence interval: 0.60 to 0.71; p < 0.001). Regarding hospital mortality among COVID-19 patients, the multivariable model indicated that there were no differences between the statin therapy and control groups (odds ratio: 0.74, 95% confidence interval: 0.52 to 1.05; p = 0.094). Statin therapy may have potential benefits for the prevention of COVID-19 in South Korea. However, we found that statin therapy does not affect the hospital mortality of patients who are diagnosed with COVID-19. View Full-Text
Keywords: hydroxymethylglutaryl-CoA reductase inhibitors; infections; hospital mortality hydroxymethylglutaryl-CoA reductase inhibitors; infections; hospital mortality
Show Figures

Figure 1

MDPI and ACS Style

Oh, T.K.; Song, I.-A.; Jeon, Y.-T. Statin Therapy and the Risk of COVID-19: A Cohort Study of the National Health Insurance Service in South Korea. J. Pers. Med. 2021, 11, 116. https://doi.org/10.3390/jpm11020116

AMA Style

Oh TK, Song I-A, Jeon Y-T. Statin Therapy and the Risk of COVID-19: A Cohort Study of the National Health Insurance Service in South Korea. Journal of Personalized Medicine. 2021; 11(2):116. https://doi.org/10.3390/jpm11020116

Chicago/Turabian Style

Oh, Tak K.; Song, In-Ae; Jeon, Young-Tae. 2021. "Statin Therapy and the Risk of COVID-19: A Cohort Study of the National Health Insurance Service in South Korea" J. Pers. Med. 11, no. 2: 116. https://doi.org/10.3390/jpm11020116

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop